Status:
COMPLETED
Dexmedetomidine on Microcirculation in Septic Shock
Lead Sponsor:
Southeast University, China
Conditions:
Septic Shock
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
Dexmedetomidine was found might be beneficial to sepsis. Dexmedetomidine were found to improve microcirculation in sepsis animal studies and non-sepsis patients. However, the effect of dexmedetomidine...
Detailed Description
Septic shock is characterized by significant decline in vascular response and relative hypovolemia. Fluids and exogenous catecholamines are mainstay. However, even after initial resuscitation, microci...
Eligibility Criteria
Inclusion
- Adult patients who met the following inclusion criteria were enrolled in the study: 1) With septic shock defined by the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference for less than 24 hours.
- 2\) After initial fluid resuscitation but still requiring norepinephrine to maintain arterial pressure or hyperlactacidemia.
- 3\) Need ongoing analgesia and sedation. 4) Using advanced invasive hemodynamic monitoring techniques.
- Exclusion criteria were as follows:
- age less than 18 years.
- pregnancy.
- heart rate less than 55 beats per minute.
- acute hepatic failure
- brain injury.
Exclusion
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2017
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT02270281
Start Date
December 1 2014
End Date
May 1 2017
Last Update
December 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China, 210000